Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 9/20 | 0.60 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.60 |
| ▸ | MAPT | P10636 | 6/20 | 0.60 |
| ▸ | NFKB1 | P19838 | 3/20 | 0.60 |
| ▸ | NFKB2 | Q00653 | 3/20 | 0.60 |
| ▸ | RELA | Q04206 | 3/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.60 |
| ▸ | LMNA | P02545 | 1/20 | 0.60 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.60 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.60 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.60 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.60 |
| ▸ | HTT | P42858 | 1/20 | 0.60 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.60 |
| ▸ | KDR | P35968 | 1/20 | 0.51 |
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | MEN1 | O00255 | 5/20 | 0.50 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | CASP3 | P42574 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112095 | 0.85 | NPC1 (0.60) | NPC1KMT2AMAPTNFKB1NFKB2 | |
| SCHEMBL17485927 | 0.82 | NPC1 (0.57) | NPC1KMT2AMAPTNFKB1NFKB2 | |
| SCHEMBL5174953 | 0.78 | KCNN1 (0.61) | NPC1KMT2AKDM4ESLC2A1KDR | |
| SCHEMBL16112445 | 0.76 | DHODH (0.54) | NPC1KMT2AMAPTNFKB1NFKB2 | |
| SCHEMBL30745670 | 0.75 | NPC1 (1.00) | NPC1KMT2AMAPTNFKB1NFKB2 | |
| SCHEMBL16112373 | 0.75 | NPC1 (1.00) | NPC1KMT2AMAPTNFKB1NFKB2 | |
| SCHEMBL16137405 | 0.74 | NPC1 (0.47) | NPC1KMT2AMAPTNFKB1NFKB2 | |
| SCHEMBL5110748 | 0.72 | KDR (0.48) | NPC1KMT2AMAPTNFKB1NFKB2 | |
| SCHEMBL1017978 | 0.71 | KMT2A (0.51) | NPC1KMT2AMAPTKDM4ELMNA | |
| SCHEMBL15993389 | 0.70 | GRM4 (0.48) | NPC1KMT2AMAPTNFKB1NFKB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | THE BROAD INSTITUTE, INC. (US) | 2019-03-05 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE GENERAL HOSPITAL CORPORATION | 2017-10-26 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-02-04 | — | — | US | disclosed |
| WO-2014159938-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | THE BROAD INSTITUTE, INC. (US) | 2014-10-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170305895-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | AADAT, ABAT, AASDHPPT | NPC1 2775/4885KMT2A 1460/4885MAPT 107/4885 |
| US-20160031874-A1 | SUBSTITUTED AMINOTHIAZOLES FOR THE TREATMENT OF TUBERCULOSIS | ABAT, AADAT, AASDHPPT | NPC1 2013/4885KMT2A 2026/4885MAPT 295/4885 |
| US-10221169-B2 | Substituted aminothiazoles for the treatment of tuberculosis | AADAT, ABAT, AASDHPPT | NPC1 2775/4885KMT2A 1460/4885MAPT 107/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.